SBIR/STTR Research Award

A Novel Liquid Oxygen Recharger for Home Oxygen Therapy

Award identifier 3c4cf8da46047aba32fc58b62a9f51e2aed4ae467c39e6d336bfe4c8308a98b2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,017,380

Program and phase

SBIR · Phase II

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CREARE LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
JDKYAKDT4TT6
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The specific aim of this project is to develop and demonstrate a low-cost, liquid oxygen (LOX) generation system to support ambulatory patients using Home Oxygen Therapy (HOT). Currently in the United States, yearly expenditures on HOT are nearly two billion dollars. These expenditures will increase dramatically over the next ten years due to the aging baby-boomer generation. The increase in use of LOX- based HOT systems is expected to continue due to demographics, patient and clinician preferences, and the general success of HOT as a treatment regimen. The primary drawback of LOX-based systems is the high-operational cost, because the storage reservoir for these systems must be frequently refilled with LOX. Creare's innovation is a Miniaturized LOX Generation System (MLGS). This novel device is a small, low-power, low-cost system that generates liquid oxygen from atmospheric air. The basis of the innovation is the miniaturization of the liquid oxygen systems we have developed for the military and NASA. Our novel system will directly refill the portable LOX unit, eliminating the need for the storage reservoir and the LOX re-supply infrastructure. Thus, our innovation will substantially reduce the cost of LOX-based HOT, while improving convenience, safety, and compliance. During Phase I, we clearly demonstrated the feasibility of our innovation and exceeded our technical objectives by designing, demonstrating, and optimizing a highly compact proof-of-concept system for the production of high-purity (>99%) LOX in excess of the original design flow rate. We also completed the preliminary design of a prototype that will be used for the refilling of a commercially available portable LOX unit. We have reached an agreement with a leading supplier of LOX- based HOT systems for the sales and marketing of our innovation. During Phase II, we will design, fabricate, and test the MLGS prototype and transition our innovation to our partner for commercialization.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

1,365 SBIR/STTR records share this UEI (1983–2026). Reported award amounts total $507,020,394. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Health and Human Services, Department of Energy, Department of Transportation, Department of Commerce

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.